- Home
- ACET vs MODV Comparison
ACET vs MODV Comparison
Compare ACET & MODV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- MODV
- Stock Information
- Founded
- ACET 1947
- MODV 1996
- Country
- ACET United States
- MODV United States
- Employees
- ACET N/A
- MODV N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- MODV Transportation Services
- Sector
- ACET Health Care
- MODV Consumer Discretionary
- Exchange
- ACET Nasdaq
- MODV Nasdaq
- Market Cap
- ACET 61.2M
- MODV 53.5M
- IPO Year
- ACET N/A
- MODV N/A
- Fundamental
- Price
- ACET $0.76
- MODV $3.03
- Analyst Decision
- ACET Buy
- MODV Buy
- Analyst Count
- ACET 6
- MODV 4
- Target Price
- ACET $6.00
- MODV $9.17
- AVG Volume (30 Days)
- ACET 406.7K
- MODV 845.4K
- Earning Date
- ACET 08-12-2025
- MODV 08-06-2025
- Dividend Yield
- ACET N/A
- MODV N/A
- EPS Growth
- ACET N/A
- MODV N/A
- EPS
- ACET N/A
- MODV N/A
- Revenue
- ACET N/A
- MODV $2,753,789,000.00
- Revenue This Year
- ACET N/A
- MODV N/A
- Revenue Next Year
- ACET N/A
- MODV $4.90
- P/E Ratio
- ACET N/A
- MODV N/A
- Revenue Growth
- ACET N/A
- MODV N/A
- 52 Week Low
- ACET $0.45
- MODV $0.87
- 52 Week High
- ACET $1.70
- MODV $32.82
- Technical
- Relative Strength Index (RSI)
- ACET 57.89
- MODV 49.68
- Support Level
- ACET $0.58
- MODV $2.87
- Resistance Level
- ACET $0.82
- MODV $4.20
- Average True Range (ATR)
- ACET 0.04
- MODV 0.36
- MACD
- ACET 0.01
- MODV -0.11
- Stochastic Oscillator
- ACET 74.79
- MODV 16.45
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About MODV ModivCare Inc.
ModivCare Inc is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for payors and their members. Its solutions address the social determinants of health (SDoH) by connecting members to essential care services. Its various service offerings include non-emergency medical transportation, personal care, virtual and remote monitoring, consumer health engagement, and integrated supportive care. The company's reportable segments are NEMT, PCS, Monitoring, and Corporate and Other. A majority of its revenue is generated from the NEMT segment, which provides non-emergency medical transportation services.